tirzepatide and testosterone On Tirzepatide? Don't skip this.

In the ATTAIN-2 trial (participants with obesity and type 2 diabetes), GI adverse event rates were somewhat higher than in ATTAIN-1: nausea 20.1-36.4% versus 8.4% with placebo, vomiting 12.8-23.1% versus 3.8%, diarrhea 21.3-27.4% versus 15.0%, and constipation 17.7-22.4% versus 7.8%

Risk Management Sponsors must implement risk management strategies to minimize potential risks associated with investigational medicinal products

This anti-ageing face cream with peptides provides intensive moisture, improves skin texture and helps reduce the appearance of wrinkles and fine lines

Aronne LJ, Horn DB, le Roux CW, Ho W, Falcon BL, Gomez Valderas E, Das S, Lee CJ, Glass LC, Senyucel C, Dunn JP